Over the past 5 years, the Center sustained its upward trajectory in cancer research excellence and service to its catchment area, the State of North Carolina. With Dr Sharpless?s appointment to NCI Director, in consultation with University leadership and the Center?s Scientific Advisors, Dr Earp was re-appointed UNC Lineberger Comprehensive Cancer Center (LCCC) Director for an additional term. The LCCC continued its exceptional performance of the past decade with respect to all important metrics including state service. Direct cost cancer research funding in 2019 increased to $161M of which over $54M comes from NCI; Center research space under the Director?s authority increased by ~10,000nsf; participation in interventional trials was over 11,000 accruals for the 5 year period; 36% of the more than 6,000 cancer related publication were collaborative; construction of a GMP facility was begun and a CAR T program was initiated with multiple INDs and 8 trials opened; and the Office of Community Outreach Engagement expanded LCCC?s traditional strength in community-based participatory research and implementation . The Center?s 324 members span the basic, clinical and population sciences organized into 9 programs with substantial inter- and intra-programmatic productivity. Faculty additions in the physical and pharmaceutical sciences created new opportunities in drug discovery, delivery, imaging and early detection. Substantial investment in faculty, technology and bioinformatics dramatically expanded cancer genetics research including leadership in the TCGA and expanded use of sequencing in clinical trials. LCCC population scientists initiated significant new efforts in cancer outcomes with recruitment and infrastructure for analyzing all cancer cases in our catchment area, as well as new endeavors in cancer communication, health access, survivorship and molecular epidemiology. Groundbreaking observations in breast cancer minority disparity research emerged from Center programs. Our basic programs continue to publish high-impact observations that are being translated into human therapeutics. A trans-Center Global Oncology effort received grants in each of the NCI?s new competitions. The Center?s continued expansion is driven by remarkable institutional support including direct support for cancer research from the state legislature. The UNC Lineberger requests continued funding for: 9 scientific programs; 13 shared resources; Clinical Protocol and Data Management; Protocol Review and Monitoring System, Developmental Funds, Planning, Leadership and Evaluation and Cancer Research and Career Enhancement The CCSG budget supports technological and operational expansion for a talented faculty integrated through cancer center mechanisms towards making advancements in the prevention, early detection, and treatment of cancer in North Carolina and the nation.
The Lineberger Comprehensive Cancer Center (LCCC) forms the nexus for researchers focused on understanding and identifying the mechanisms leading to, the prevention of, and treatments for cancer. LCCC is an integral component of the research mission at The University of North Carolina (UNC) at Chapel Hill, coalescing the cancer research capabilities of the Schools of Medicine, Public Health, Pharmacy, and Nursing, and the College of Arts and Sciences. The LCCC strives to reduce cancer incidence, morbidity, and mortality in North Carolina, the United States and across the globe through innovative research, cutting-edge treatments, multi-disciplinary training, education and outreach.
|Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163|
|Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63|
|Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267|
|Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732|
|Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:|
|Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6|
|Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:|
|Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024|
|Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468|
|Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295|
Showing the most recent 10 out of 1525 publications